1
|
Manier S, Park J, Capelletti M, Bustoros M, Freeman SS, Ha G, Rhoades J, Liu CJ, Huynh D, Reed SC, Gydush G, Salem KZ, Rotem D, Freymond C, Yosef A, Perilla-Glen A, Garderet L, Van Allen EM, Kumar S, Love JC, Getz G, Adalsteinsson VA, Ghobrial IM. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma. Nat Commun 2018; 9:1691. [PMID: 29703982 PMCID: PMC5923255 DOI: 10.1038/s41467-018-04001-5] [Citation(s) in RCA: 128] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2017] [Accepted: 03/27/2018] [Indexed: 12/29/2022] Open
Abstract
Liquid biopsies including circulating tumor cells (CTCs) and cell-free DNA (cfDNA) have enabled minimally invasive characterization of many cancers, but are rarely analyzed together. Understanding the detectability and genomic concordance of CTCs and cfDNA may inform their use in guiding cancer precision medicine. Here, we report the detectability of cfDNA and CTCs in blood samples from 107 and 56 patients with multiple myeloma (MM), respectively. Using ultra-low pass whole-genome sequencing, we find both tumor fractions correlate with disease progression. Applying whole-exome sequencing (WES) to cfDNA, CTCs, and matched tumor biopsies, we find concordance in clonal somatic mutations (~99%) and copy number alterations (~81%) between liquid and tumor biopsies. Importantly, analyzing CTCs and cfDNA together enables cross-validation of mutations, uncovers mutations exclusive to either CTCs or cfDNA, and allows blood-based tumor profiling in a greater fraction of patients. Our study demonstrates the utility of analyzing both CTCs and cfDNA in MM. Circulating tumor cells (CTCs) and cell-free DNA (cfDNA) enables characterization of a patient’s cancer. Here, the authors analyse CTCs, cfDNA, and tumor biopsies from multiple myeloma patients to show these approaches are complementary for mutation detection, together enabling a greater fraction of patient tumors to be profiled.
Collapse
Affiliation(s)
- S Manier
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA.,Hematology Department, CHU, Univ. Lille, 59000, Lille, France.,INSERM UMR-S1172, 59000, Lille, France
| | - J Park
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA.,Brigham and Women's Hospital, Boston, MA, 02115, USA
| | - M Capelletti
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA
| | - M Bustoros
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA
| | - S S Freeman
- Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA
| | - G Ha
- Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA
| | - J Rhoades
- Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA
| | - C J Liu
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA
| | - D Huynh
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA
| | - S C Reed
- Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA
| | - G Gydush
- Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA
| | - K Z Salem
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA
| | - D Rotem
- Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA
| | - C Freymond
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA
| | - A Yosef
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA
| | - A Perilla-Glen
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA
| | - L Garderet
- Department of Hematology, St-Antoine University Hospital, Paris, 75000, France
| | - E M Van Allen
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA.,Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA
| | - S Kumar
- Department of Hematology, Mayo Clinic, Rochester, MN, 55902, USA
| | - J C Love
- Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA
| | - G Getz
- Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA
| | - V A Adalsteinsson
- Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
| | - I M Ghobrial
- Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02115, USA. .,Brigham and Women's Hospital, Boston, MA, 02115, USA. .,Cancer Program, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
| |
Collapse
|